NASDAQ: DXCMDexcom Inc Stock
$82.93-0.65 (-0.78%)
Updated Jul 3, 2025
DXCM Price
$82.93
Fair Value Price
$31.24
Market Cap
$32.52B
52 Week Low
$57.52
52 Week High
$117.19
P/E
61.43x
P/B
14.35x
P/S
6.44x
PEG
1.92x
Dividend Yield
N/A
Revenue
$4.15B
Earnings
$535.20M
Gross Margin
59.4%
Operating Margin
18.08%
Profit Margin
12.9%
Debt to Equity
1.98
Operating Cash Flow
$964M
Beta
1.2
Next Earnings
Jul 23, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DXCM Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DXCM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
DXCM
Ranked#25 of 106
Ranked#25 of 106
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.35 | A | |
| $30.28 | A | |
| $237.55 | A |
Be the first to know about important DXCM news, forecast changes, insider trades & much more!
DXCM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DXCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DXCM ($82.93) is overvalued by 165.45% relative to our estimate of its Fair Value price of $31.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DXCM ($82.93) is not significantly undervalued (165.45%) relative to our estimate of its Fair Value price of $31.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DXCM ($82.93) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DXCM due diligence checks available for Premium users.
Valuation
DXCM fair value
Fair Value of DXCM stock based on Discounted Cash Flow (DCF)
Price
$82.93
Fair Value
$31.24
Overvalued by
165.45%
DXCM ($82.93) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DXCM ($82.93) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DXCM ($82.93) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DXCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
61.43x
Industry
36.28x
Market
30.96x
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DXCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.35x
Industry
4.1x
DXCM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DXCM price to earnings growth (PEG)
For valuing profitable companies with growth potential
DXCM is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DXCM's financial health
Profit margin
Revenue
$1.0B
Net Income
$105.4M
Profit Margin
10.2%
DXCM's Earnings (EBIT) of $749.80M... subscribe to Premium to read more.
Interest Coverage Financials
DXCM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.8B
Liabilities
$4.5B
Debt to equity
1.98
DXCM's short-term assets ($4.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DXCM's short-term assets ($4.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DXCM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DXCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$183.8M
Investing
$100.2M
Financing
$12.5M
DXCM's operating cash flow ($964.10M)... subscribe to Premium to read more.
Debt Coverage Financials
DXCM vs Medical Device Stocks
Dexcom Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.